导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.31% | 1244/4773 |
| 近一周 | -2.60% | 2638/5462 |
| 近一月 | -5.08% | 3045/5421 |
| 近一季 | -5.90% | 1940/5209 |
| 近半年 | -4.80% | 2626/4920 |
| 近一年 | 8.86% | 1144/4366 |
| 近两年 | 72.82% | 924/2954 |
| 近三年 | 33.40% | 919/2253 |
| 成立以来 | 142.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.49% 915/4961 |
14.95% 1734/5312 |
- - |
- - |
| 2025 | 31.70% 1220/4813 |
3.17% 1171/3635 |
3.96% 898/4076 |
20.04% 2047/4524 |
2.29% 1007/4813 |
| 2024 | 1.64% 1998/3463 |
-6.56% 2063/2808 |
-3.15% 1306/3014 |
12.59% 2315/3129 |
-0.24% 1355/3463 |
| 2023 | -4.69% 691/2656 |
8.24% 476/2280 |
-5.03% 1350/2385 |
-3.47% 938/2515 |
-3.95% 826/2655 |
| 2022 | -23.56% 1147/2207 |
-14.26% 928/1919 |
3.63% 1121/2016 |
-10.30% 378/2113 |
-4.08% 1883/2208 |
| 2021 | 21.14% 167/1822 |
-0.30% 348/1255 |
9.37% 558/1330 |
6.80% 210/1466 |
4.03% 373/1822 |
| 2020 | 39.74% 326/1250 |
-2.14% 255/1028 |
24.73% 163/1067 |
8.08% 738/1164 |
5.92% 769/1184 |
| 2019 | 20.81% 659/1092 |
20.27% 611/754 |
-7.94% 576/804 |
1.71% 366/850 |
7.28% 457/918 |
| 2018 | -32.77% 538/834 |
- - |
- - |
- - |
-9.24% 138/691 |
| 2017 | 17.59% 223/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.97% 391/605 |
- - |
- - |
- - |
- - |
| 2015 | 18.17% 128/575 |
- - |
- - |
- - |
- - |
| 2014 | 22.31% 188/237 |
- - |
- - |
- - |
- - |
| 2013 | 26.35% 10/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 海富通中证500增强A VS. 长安沪深300非周期A(740101) |